{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:34:15Z","timestamp":1782761655918,"version":"3.54.5"},"reference-count":110,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1053\/j.semnuclmed.2020.07.008","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T01:56:27Z","timestamp":1596765387000},"page":"68-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Role of Non-FDG-PET\/CT in Head and Neck Cancer"],"prefix":"10.1053","volume":"51","author":[{"given":"Charles","family":"Marcus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathan M.","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0001","article-title":"Nation Cancer Institute: Surveillance, Epidemiology, and End Results Program","year":"2020","journal-title":"Cancer Stat Facts"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/jop.12943","article-title":"A review of recent advances in histopathological assessment of head and neck squamous cell carcinoma","volume":"49","author":"Chegini","year":"2020","journal-title":"J Oral Pathol Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/cncy.22258","article-title":"Determination of high\u2010risk HPV status of head and neck squamous cell carcinoma using the Roche Cobas HPV test on cytologic specimens and acellular supernatant fluid","author":"Wright","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0004","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1200\/JCO.18.01182","article-title":"Multicenter trial of [18 F]fluorodeoxyglucose positron emission tomography\/computed tomography staging of head and neck cancer and negative predictive value and surgical impact in the N0 neck: Results from ACRIN 6685","volume":"37","author":"Lowe","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0005","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","article-title":"PET-CT surveillance versus neck dissection in advanced head and neck cancer","volume":"374","author":"Mehanna","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0006","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1200\/JCO.2017.73.5845","article-title":"Fluorodeoxyglucose-positron emission tomography\/computed tomography after concurrent chemoradiotherapy in locally advanced head-and-neck squamous cell cancer: The ECLYPS study","volume":"35","author":"Van den Wyngaert","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0007","series-title":"NCCN Guideline Version","first-page":"12020","article-title":"NCCN clinical practice guidelines in oncology: Head and neck cancers","year":"2020"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0008","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1097\/RLU.0000000000002247","article-title":"Update 2018: 18F-FDG PET\/CT and PET\/MRI in head and neck cancer","volume":"43","author":"Sanli","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0009","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.oooo.2017.05.506","article-title":"18 F-fluoromisonidazole positron emission tomography (FMISO-PET) may reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma","volume":"124","author":"Sato","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.ijrobp.2009.07.009","article-title":"Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases","volume":"77","author":"Jansen","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0011","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3109\/0284186X.2015.1067721","article-title":"Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia\u2014A simulation study","volume":"54","author":"Wack","year":"2015","journal-title":"Acta Oncol (Madr)"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0012","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/MNM.0000000000001016","article-title":"Correlation between tumour biology status measured in triple-tracer 18F-fluorodeoxyglucose\u201318F-fluorothymidine\u201318F-fluoromisonidazole-PET\/CT study and human papillomavirus status in patients with head and neck cancer","volume":"40","author":"Cegla","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12149-011-0508-9","article-title":"18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma","volume":"25","author":"Kikuchi","year":"2011","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0014","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00066-013-0454-7","article-title":"Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas","volume":"189","author":"Henriques de Figueiredo","year":"2013","journal-title":"Strahlentherap Onkol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0360-3016(92)91001-4","article-title":"Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole","volume":"22","author":"Koh","year":"1992","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0016","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/BF01367595","article-title":"Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma","volume":"23","author":"Yeh","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0017","first-page":"108","article-title":"Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients","volume":"15","author":"Bandurska-Luque","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0018","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.radonc.2017.11.025","article-title":"Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-fluorodeoxyglucose positron emission tomography radiomics features","volume":"127","author":"Crispin-Ortuzar","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0019","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ijrobp.2007.09.050","article-title":"The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography","volume":"70","author":"Lin","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0020","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3109\/0284186X.2012.759273","article-title":"Hypoxia-targeted radiotherapy dose painting for head and neck cancer using 18 F-FMISO PET: A biological modeling study","volume":"52","author":"Chang","year":"2013","journal-title":"Acta Oncol (Madr)"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0021","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.radonc.2011.07.029","article-title":"Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance","volume":"101","author":"Hendrickson","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0022","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1080\/0284186X.2017.1372626","article-title":"Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer","volume":"56","author":"Boeke","year":"2017","journal-title":"Acta Oncol (Madr)"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijrobp.2016.04.027","article-title":"Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human papillomavirus-related oropharyngeal carcinoma","volume":"96","author":"Lee","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0024","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-005-1880-2","article-title":"Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent","volume":"32","author":"Hicks","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0025","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00259-014-2810-y","article-title":"Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma","volume":"41","author":"Sato","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0026","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11307-010-0365-2","article-title":"Reduction of [18F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma","volume":"13","author":"Yamane","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0027","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00259-016-3431-4","article-title":"The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy","volume":"43","author":"Okamoto","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0028","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.radonc.2017.08.010","article-title":"Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging","volume":"124","author":"L\u00f6ck","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0029","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2008.10.049","article-title":"Prospective trial incorporating pre-\/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy","volume":"75","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0030","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.2967\/jnumed.119.227744","article-title":"Prospective evaluation of a tumor control probability model based on dynamic 18 F-FMISO PET for head and neck cancer radiotherapy","volume":"60","author":"Thorwarth","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0031","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2967\/jnumed.116.188649","article-title":"Multiparametric imaging of tumor hypoxia and perfusion with 18 F-fluoromisonidazole dynamic PET in head and neck cancer","volume":"58","author":"Grkovski","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0032","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2967\/jnumed.115.160168","article-title":"Feasibility of 18F-fluoromisonidazole kinetic modeling in head and neck cancer using shortened acquisition times","volume":"57","author":"Grkovski","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0033","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijom.2017.09.007","article-title":"Hypoxic volume evaluated by 18 F-fluoromisonidazole positron emission tomography (FMISO-PET) may be a prognostic factor in patients with oral squamous cell carcinoma: Preliminary analyses","volume":"47","author":"Sato","year":"2018","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2020.05.022","article-title":"Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy","author":"Zschaeck","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.radonc.2018.09.008","article-title":"FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients","volume":"130","author":"Bandurska-Luque","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0036","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s00259-019-04609-9","article-title":"Textural features of hypoxia PET predict survival in head and neck cancer during chemoradiotherapy","volume":"47","author":"S\u00f6rensen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0037","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2012.08.019","article-title":"Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer","volume":"105","author":"Zips","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0038","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijrobp.2007.08.036","article-title":"Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer","volume":"70","author":"Nehmeh","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0039","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jtos.2012.07.002","article-title":"Wakayama symposium: Challenges of future research in ocular surface cell biology","volume":"11","author":"Kao","year":"2013","journal-title":"Ocul Surf"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0040","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00259-009-1154-5","article-title":"Initial results of hypoxia imaging using 1-\u03b1-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)","volume":"36","author":"Postema","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0041","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00259-014-2730-x","article-title":"A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy","volume":"41","author":"Servagi-Vernat","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0042","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3109\/0284186X.2014.990109","article-title":"Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: A planning study","volume":"54","author":"Servagi-Vernat","year":"2015","journal-title":"Acta Oncol (Madr)"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0043","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.radonc.2014.10.010","article-title":"Dynamics of tumor hypoxia assessed by 18F-FAZA PET\/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategies","volume":"113","author":"Bollineni","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0044","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12149-015-1048-5","article-title":"Prognostic value of PET\/CT with 18F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy","volume":"30","author":"Saga","year":"2016","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.radonc.2012.09.015","article-title":"FAZA PET\/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial","volume":"105","author":"Mortensen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0046","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/MNM.0b013e3283571016","article-title":"18F-HX4 hypoxia imaging with PET\/CT in head and neck cancer","volume":"33","author":"Chen","year":"2012","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0047","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1007\/s00259-015-3100-z","article-title":"Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: A prospective multicenter trial","volume":"42","author":"Zegers","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0048","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3109\/0284186X.2015.1062913","article-title":"Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma","volume":"54","author":"Zegers","year":"2015","journal-title":"Acta Oncol (Madr)"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0049","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MNM.0000000000000933","article-title":"Hypoxia imaging with [18F]HX4 PET in squamous cell head and neck cancers","volume":"40","author":"Betts","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0050","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00259-016-3429-y","article-title":"Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer","volume":"43","author":"Zegers","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0051","first-page":"9","article-title":"[18F]-HX4 PET\/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials","volume":"23","author":"Sanduleanu","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0052","first-page":"1397","article-title":"Pharmacokinetics of [18F]FETNIM: A potential hypoxia marker for PET","volume":"42","author":"Gr\u00f6nroos","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0053","first-page":"1643","article-title":"Imaging of blood flow and hypoxia in head and neck cancer: Initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET","volume":"42","author":"Lehti\u00f6","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0054","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ijrobp.2003.12.014","article-title":"Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer","volume":"59","author":"Lehti\u00f6","year":"2004","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0055","doi-asserted-by":"crossref","first-page":"e17067","DOI":"10.1097\/MD.0000000000017067","article-title":"Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET\/CT) in locoregionally advanced head and neck cancer","volume":"98","author":"Hu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0056","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2967\/jnumed.108.053785","article-title":"18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer","volume":"49","author":"Komar","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0057","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00259-017-3857-3","article-title":"Repeatability of tumour hypoxia imaging using [18F]EF5 PET\/CT in head and neck cancer","volume":"45","author":"Silvoniemi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0058","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1007\/s00259-014-2818-3","article-title":"Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET\/CT imaging in patients with head and neck cancer treated with radiochemotherapy","volume":"41","author":"Komar","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0059","first-page":"1155","article-title":"Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential","volume":"38","author":"Fujibayashi","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0060","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/RLU.0b013e31823eaadb","article-title":"Different distribution of 62Cu ATSM and 18F-FDG in head and neck cancers","volume":"37","author":"Kositwattanarerk","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0061","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12149-011-0471-5","article-title":"Assessment of tumor hypoxia by 62Cu-ATSM PET\/CT as a predictor of response in head and neck cancer: a pilot study","volume":"25","author":"Minagawa","year":"2011","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0062","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0360-3016(00)01433-4","article-title":"A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy","volume":"49","author":"Chao","year":"2001","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0063","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/RLU.0000000000000537","article-title":"Assessing tumor hypoxia in head and neck cancer by PET with 62Cu-diacetyl-bis(N4-methylthiosemicarbazone)","volume":"39","author":"Sato","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0064","first-page":"1393","article-title":"Carbon-11-methionine uptake in squamous cell head and neck cancer","volume":"39","author":"Lindholm","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/coa.13242","article-title":"Is C-11 methionine PET an alternative to 18-F FDG-PET for identifying recurrent laryngeal cancer after radiotherapy?","volume":"44","author":"Wedman","year":"2019","journal-title":"Clin Otolaryngol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0066","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2004.02.013","article-title":"Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: Comparison with FDG-PET and CT","volume":"71","author":"Geets","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0067","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.radonc.2004.09.009","article-title":"11C-methionine PET, a novel method for measuring regional salivary gland function after radiotherapy of head and neck cancer","volume":"73","author":"Buus","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0068","first-page":"205","article-title":"Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging","volume":"40","author":"Wester","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0069","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00259-002-0863-9","article-title":"Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas","volume":"29","author":"de Boer","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12149-013-0701-0","article-title":"Clinical significance of 18F-\u03b1-methyl tyrosine PET\/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: Comparison with 18F-FDG PET\/CT and MRI","volume":"27","author":"Kim","year":"2013","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0071","first-page":"256","article-title":"18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer","volume":"47","author":"Pauleit","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0072","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s11307-010-0419-5","article-title":"18F-FET PET\/CT in advanced head and neck squamous cell carcinoma: An intra-individual comparison with 18F-FDG PET\/CT","volume":"13","author":"Haerle","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0073","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11307-008-0155-2","article-title":"Prospective comparison of FDG and FET PET\/CT in patients with head and neck squamous cell carcinoma","volume":"10","author":"Balogova","year":"2008","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0074","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-004-1496-y","article-title":"Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors","volume":"31","author":"Tian","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF02984484","article-title":"Positron emission tomographic imaging with11C-choline in differential diagnosis of head and neck tumors: Comparison with18F-FDG PET","volume":"18","author":"Khan","year":"2004","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0076","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00259-010-1400-x","article-title":"18F-FDG versus 11C-choline PET\/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: The time period during which PET\/CT can reliably detect non-recurrence","volume":"37","author":"Ito","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0077","first-page":"32","article-title":"In vivo demonstration of enzyme activity in endocrine pancreatic tumors: Decarboxylation of carbon-11-DOPA to carbon-11-dopamine","volume":"37","author":"Bergstr\u00f6m 1","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0078","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s002590000404","article-title":"18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels","volume":"28","author":"Hoegerle","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0079","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2967\/jnumed.111.094771","article-title":"Complementary roles of 18F-DOPA PET\/CT and 18F-FDG PET\/CT in medullary thyroid cancer","volume":"52","author":"Kauhanen","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2009.0342","article-title":"Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma","volume":"20","author":"Luster","year":"2010","journal-title":"Thyroid"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0081","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.acra.2012.05.008","article-title":"Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography","volume":"19","author":"Treglia","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0082","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12149-018-1265-9","article-title":"Correction to: Predictive and prognostic value of 18F-DOPA PET\/CT in patients affected by recurrent medullary carcinoma of the thyroid","volume":"32","author":"Caobelli","year":"2018","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0083","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hed.20770","article-title":"Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts","volume":"30","author":"Atkinson","year":"2008","journal-title":"Head Neck"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0084","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.radonc.2012.09.012","article-title":"Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx","volume":"105","author":"Nyflot","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0085","first-page":"226","article-title":"18F-FLT PET for visualization of laryngeal cancer: Comparison with 18F-FDG PET","volume":"45","author":"Cobben","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0086","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.joms.2015.01.002","article-title":"Can 3\u2032-deoxy-3\u2032-(18F) fluorothymidine outperform 2-deoxy-2-(18F) fluoro-d-glucose positron emission tomography\/computed tomography in the diagnosis of cervical lymphadenopathy in patients with oral\/head and neck cancer?","volume":"73","author":"Schaefferkoetter","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0087","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2967\/jnumed.106.037473","article-title":"18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients","volume":"48","author":"Troost","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0088","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1097\/RLU.0b013e3182815fe1","article-title":"The value of 18F-FLT PET for detecting second primary cancers and distant metastases in head and neck cancer patients","volume":"38","author":"Hoshikawa","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0089","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ijrobp.2014.11.029","article-title":"Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion","volume":"91","author":"Nyflot","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0090","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.109.069310","article-title":"18F-FLT PET\/CT for early response monitoring and dose escalation in oropharyngeal tumors","volume":"51","author":"Troost","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0091","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12149-013-0694-8","article-title":"Changes in 18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy","volume":"27","author":"Hoshikawa","year":"2013","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0092","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2967\/jnumed.111.099200","article-title":"Usefulness of 3\u2019-deoxy-3\u2019-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer","volume":"53","author":"Kishino","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0093","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.21873\/anticanres.12708","article-title":"Hybrid imaging PET\/CT with application of 18 F-fluorothymidine in patients with head and neck carcinoma undergoing radiotherapy","volume":"38","author":"Baxa","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0094","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s12149-014-0902-1","article-title":"Predictive value of SUV-based parameters derived from pre-treatment 18F-FLT PET\/CT for short-term outcome with head and neck cancers","volume":"28","author":"Hoshikawa","year":"2014","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0095","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180781","article-title":"Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment","volume":"93","author":"Kazmierska","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0096","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/RLU.0000000000000652","article-title":"Prognostic value comparison between 18F-FLT PET\/CT and 18F-FDG PET\/CT volume-based metabolic parameters in patients with head and neck cancer","volume":"40","author":"Hoshikawa","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0097","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00259-013-2651-0","article-title":"Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET\/CT images in head and neck carcinomas and their relation to clinical outcome","volume":"41","author":"Arens","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0098","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2967\/jnumed.112.105999","article-title":"18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome","volume":"54","author":"Hoeben","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0099","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18383\/j.tom.2018.00038","article-title":"FLT PET radiomics for response prediction to chemoradiation therapy in head and neck squamous cell cancer","volume":"5","author":"Ulrich","year":"2019","journal-title":"Tomography"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0100","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00259-014-2723-9","article-title":"Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: Comparison with 18F-FDG PET-CT","volume":"41","author":"Kundu","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0101","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2967\/jnumed.115.171942","article-title":"68Ga-DOTATOC PET\/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin","volume":"57","author":"Binse","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0102","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00259-016-3378-5","article-title":"[68Ga]DOTATATE PET\/MRI and [18F]FDG PET\/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer","volume":"43","author":"Vrachimis","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0103","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MNM.0000000000000240","article-title":"Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma","volume":"36","author":"Ozkan","year":"2015","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0104","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00259-017-3701-9","article-title":"68Ga-DOTATATE PET\/CT in recurrent medullary thyroid carcinoma: A lesion-by-lesion comparison with 111In-octreotide SPECT\/CT and conventional imaging","volume":"44","author":"Yamaga","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0105","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1097\/RLU.0b013e318279b976","article-title":"68Ga DOTANOC PET\/CT for accurate delineation of disease extent in a case of sinonasal small cell neuroendocrine carcinoma","volume":"38","author":"Singhal","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0106","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1210\/jc.2012-4046","article-title":"A rare case of neuroendocrine tumor of the middle ear detected by gallium-68-DOTANOC-PET\/CT","volume":"98","author":"Treglia","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0107","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-014-2905-5","article-title":"68Ga-DOTA0-Tyr3-octreotide positron emission tomography in nasopharyngeal carcinoma","volume":"42","author":"Schartinger","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0108","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/hed.24164","article-title":"68 Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma","volume":"38","author":"Khor","year":"2016","journal-title":"Head Neck"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0109","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s00259-015-3012-y","article-title":"Correlation between 68Ga-DOTA-NOC PET\/CT and 18F-FDG PET\/CT in EBV-positive undifferentiated nasopharyngeal carcinoma","volume":"42","author":"Khor","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2020.07.008_bib0110","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00259-013-2442-7","article-title":"68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma","volume":"40","author":"Schartinger","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299820300799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299820300799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:36:38Z","timestamp":1757543798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299820300799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0001299820300799"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.07.008","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Non-FDG-PET\/CT in Head and Neck Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2020.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}